-
公开(公告)号:US20110008345A1
公开(公告)日:2011-01-13
申请号:US12744799
申请日:2008-11-28
申请人: Claire Ashman , Thil Batuwangala , Michael Neil Burden , Stephanie Jane Clegg , Rudolf Maria De Wildt , Jonathan Henry Ellis , Paul Andrew Hamblin , Farhana Hussain , Laurent Jespers , Alan Lewis , Martin Anibal Orecchia , Radha Shah , Michael Steward
发明人: Claire Ashman , Thil Batuwangala , Michael Neil Burden , Stephanie Jane Clegg , Rudolf Maria De Wildt , Jonathan Henry Ellis , Paul Andrew Hamblin , Farhana Hussain , Laurent Jespers , Alan Lewis , Martin Anibal Orecchia , Radha Shah , Michael Steward
IPC分类号: A61K39/395 , C07K16/24 , C07H21/04 , C12N5/10 , C12P21/04 , A61P35/00 , A61P11/06 , A61P19/02
CPC分类号: C07K16/244 , C07K16/22 , C07K16/241 , C07K16/247 , C07K16/2863 , C07K16/2866 , C07K16/2887 , C07K16/32 , C07K16/468 , C07K2317/14 , C07K2317/31 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/569 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2318/20 , C07K2319/30
摘要: The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof.
摘要翻译: 本发明涉及包含与一个或多个表位结合结构域连接的蛋白质支架的抗原结合构建体,其中所述抗原结合构建体具有至少两个抗原结合位点,其中至少一个抗原结合位点来自表位结合结构域,并且至少 其中一个来自配对的VH / VL结构域,制备此类构建体的方法及其用途。
-
公开(公告)号:US20090148905A1
公开(公告)日:2009-06-11
申请号:US12324905
申请日:2008-11-28
申请人: Claire ASHMAN , Thil Batuwangala , Michael Neil Burden , Stephanie Jane Clegg , Rudolf Maria De Wildt , Jonathan Henry Ellis , Paul Andrew Hamblin , Farhana Hussain , Laurent Jespers , Alan Lewis , Martin Anibal Orecchia , Radha Shah , Michael Steward
发明人: Claire ASHMAN , Thil Batuwangala , Michael Neil Burden , Stephanie Jane Clegg , Rudolf Maria De Wildt , Jonathan Henry Ellis , Paul Andrew Hamblin , Farhana Hussain , Laurent Jespers , Alan Lewis , Martin Anibal Orecchia , Radha Shah , Michael Steward
IPC分类号: C12P21/02 , C07K16/00 , C07H21/00 , A61K39/395 , C12N5/10
CPC分类号: C07K16/244 , C07K16/22 , C07K16/241 , C07K16/247 , C07K16/2863 , C07K16/2866 , C07K16/2887 , C07K16/32 , C07K16/468 , C07K2317/14 , C07K2317/31 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/569 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2318/20 , C07K2319/30
摘要: The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof.
摘要翻译: 本发明涉及包含与一个或多个表位结合结构域连接的蛋白质支架的抗原结合构建体,其中所述抗原结合构建体具有至少两个抗原结合位点,其中至少一个抗原结合位点来自表位结合结构域,并且至少 其中一个来自配对的VH / VL结构域,制备此类构建体的方法及其用途。
-
公开(公告)号:US20140205604A1
公开(公告)日:2014-07-24
申请号:US14235330
申请日:2012-07-25
IPC分类号: C07K16/22
CPC分类号: C07K16/22 , A61K2039/505 , A61K2039/54 , A61K2039/70 , C07K16/46 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/565 , C07K2317/569 , C07K2317/60 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD). diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularisation, and polynucleotide sequences encoding said antigen binding constructs.
摘要翻译: 本发明涉及包含由抗体的单链Fc区分离的一个或两个表位结合结构域的抗原结合构建体,其中能够结合VEGF的每个表位结合域与包含本发明的两个抗原结合构建体的二聚体, 包含所述二聚体的药物组合物及其用于治疗与VEGF信号传导相关的疾病,例如糖尿病性黄斑水肿(DME),湿性年龄相关性黄斑变性(湿性AMD)的用途。 糖尿病性视网膜病变,视网膜静脉阻塞(RVO)和角膜新生血管形成,以及编码所述抗原结合构建体的多核苷酸序列。
-
公开(公告)号:US20100254995A1
公开(公告)日:2010-10-07
申请号:US12663501
申请日:2008-06-03
申请人: Michael Steward , Malgorzata Pupecka , Ian Thomlinson , Carolyn Enever , Laurent Jespers , Thil Dinuk Batuwangala
发明人: Michael Steward , Malgorzata Pupecka , Ian Thomlinson , Carolyn Enever , Laurent Jespers , Thil Dinuk Batuwangala
IPC分类号: A61K39/395 , C07K16/22 , C07K14/00 , A61P37/00 , A61P35/00 , A61P29/00 , A61P1/00 , A61P31/04
CPC分类号: C07K16/2878 , A61K9/007 , A61K9/0078 , A61K9/1623 , A61K9/1641 , A61K39/3955 , A61K2039/544 , A61M11/005 , A61M15/08 , A61M16/14 , C07K16/00 , C07K16/005 , C07K16/22 , C07K16/2866 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.
-
公开(公告)号:US08877186B2
公开(公告)日:2014-11-04
申请号:US12663505
申请日:2008-06-03
申请人: Michael Steward , Malgorzata Pupecka , Ian Tomlinson , Carolyn Enever , Laurent Jespers , Thil Dinuk Batuwangala
发明人: Michael Steward , Malgorzata Pupecka , Ian Tomlinson , Carolyn Enever , Laurent Jespers , Thil Dinuk Batuwangala
IPC分类号: C07K16/22 , C07K14/435 , A61K39/395 , C07K14/475 , C07K16/24 , C07K16/28
CPC分类号: C07K16/2878 , C07K16/22 , C07K16/244 , C07K16/2866 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76 , C07K2317/92
摘要: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.
摘要翻译: 本发明涉及抗蛋白酶降解的抗VEGF多肽和抗体单可变结构域(dAb),以及包含它们的拮抗剂。 多肽,dAb和拮抗剂可用于肺部给药,口服给药,递送至肺部并递送至患者胃肠道,以及治疗癌症和炎性疾病如关节炎。
-
公开(公告)号:US20140227259A1
公开(公告)日:2014-08-14
申请号:US14239196
申请日:2012-08-13
申请人: Claire Ashman , Mary Birchler , Rudolf M.T. De Wildt , Claire Holland , Alan Peter Lewis , Peter Morley , Thomas Sandal , Michael Steward
发明人: Claire Ashman , Mary Birchler , Rudolf M.T. De Wildt , Claire Holland , Alan Peter Lewis , Peter Morley , Thomas Sandal , Michael Steward
IPC分类号: C07K16/42
摘要: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.
摘要翻译: 本公开涉及具有降低与先前存在的抗体结合的能力的修饰的蛋白质和肽。 这种修饰的蛋白质/肽分子可以包含C-末端添加,延伸或标签和/或某些氨基酸取代。 这样的修饰分子(例如,融合物和缀合物)包含蛋白质,肽,抗原结合分子,抗体或抗体片段,例如单可变结构域。 本公开还涉及包含这种修饰的C-末端延伸和/或氨基酸取代的分子的组合物的用途和制剂,以及这些的生产和表达方法。
-
公开(公告)号:US10808040B2
公开(公告)日:2020-10-20
申请号:US14239196
申请日:2012-08-13
申请人: Claire Ashman , Mary Birchler , Rudolf M. T. De Wildt , Claire Holland , Alan Peter Lewis , Peter Morley , Thomas Sandal , Michael Steward
发明人: Claire Ashman , Mary Birchler , Rudolf M. T. De Wildt , Claire Holland , Alan Peter Lewis , Peter Morley , Thomas Sandal , Michael Steward
IPC分类号: C07K16/00 , A61K39/395 , C07K16/42 , C07K16/28 , C07K16/22
摘要: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.
-
公开(公告)号:US09499612B2
公开(公告)日:2016-11-22
申请号:US14235330
申请日:2012-07-25
CPC分类号: C07K16/22 , A61K2039/505 , A61K2039/54 , A61K2039/70 , C07K16/46 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/565 , C07K2317/569 , C07K2317/60 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要: The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularization, and polynucleotide sequences encoding said antigen binding constructs.
摘要翻译: 本发明涉及包含由抗体的单链Fc区分离的一个或两个表位结合结构域的抗原结合构建体,其中能够结合VEGF的每个表位结合域与包含本发明的两个抗原结合构建体的二聚体, 包含所述二聚体的药物组合物及其用于治疗与VEGF信号传导相关的疾病,例如糖尿病性黄斑水肿(DME),湿性年龄相关性黄斑变性(湿性AMD),糖尿病性视网膜病变,视网膜静脉阻塞(RVO)和角膜 新生血管形成和编码所述抗原结合构建体的多核苷酸序列。
-
公开(公告)号:US20120134982A1
公开(公告)日:2012-05-31
申请号:US13299030
申请日:2011-11-17
申请人: Fiona COOK , Gerald Gough , Michael Steward , Laurent Jespers
发明人: Fiona COOK , Gerald Gough , Michael Steward , Laurent Jespers
IPC分类号: A61K39/395 , A61P27/02
CPC分类号: C07K16/005 , A61K9/0078 , A61K2039/544 , C07K16/22 , C07K16/2866 , C07K16/2878 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要: The present invention relates to polypeptides e.g. protease resistant polypeptides, immunoglobulin (antibody) single variable domains e.g. which are protease resistant and also to vascular endothelial growth factor (VEGF) antagonists comprising these. The invention further relates to uses, formulations, and compositions comprising such polypeptides e.g. for delivery to the eye.
摘要翻译: 本发明涉及多肽,例如 蛋白酶抗性多肽,免疫球蛋白(抗体)单个可变结构域,例如 其是蛋白酶抗性的,并且还包含这些的血管内皮生长因子(VEGF)拮抗剂。 本发明还涉及包含这种多肽的用途,制剂和组合物,例如 送到眼睛。
-
公开(公告)号:US20120064064A1
公开(公告)日:2012-03-15
申请号:US13322229
申请日:2010-05-26
IPC分类号: A61K39/395 , C12N5/10 , C12N1/21 , C07K16/24 , C07K16/00 , C07K16/22 , C07H21/04 , C12P21/06 , C12N1/19
CPC分类号: C07K16/468 , A61K39/39541 , A61K39/3955 , C07K16/22 , C07K16/2863 , C07K16/2866 , C07K16/462 , C07K2317/569 , C07K2317/76
摘要: The present invention relates to antigen binding proteins comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises an epitope binding domain linked to the n-terminus of CH1-CH2-CH3, and the light chain comprises an epitope binding domain linked to the n-terminus of CL, wherein one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin heavy chain, and/or one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin light chain, methods for making such proteins, and uses thereof.
摘要翻译: 本发明涉及包含免疫球蛋白重链和免疫球蛋白轻链的抗原结合蛋白,其中重链包含与CH1-CH2-CH3的n端连接的表位结合结构域,轻链包含表位结合结构域 连接到CL的n末端,其中一个或多个表位结合结构域连接到免疫球蛋白重链的C末端,和/或一个或多个表位结合结构域连接到免疫球蛋白的C末端 轻链,制备这种蛋白质的方法及其用途。
-
-
-
-
-
-
-
-
-